Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204211 | 1.00 | JAK3 (0.61) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL9052038 | 0.96 | ACE (0.64) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL9929886 | 0.94 | CTSS (0.62) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL8185213 | 0.94 | CTSS (0.62) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL5347958 | 0.90 | BCL2 (0.59) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL6597802 | 0.90 | BCL2 (0.59) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL5347955 | 0.90 | BCL2 (0.59) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL9963893 | 0.89 | CTSS (0.60) | JAK3BTKCTSSCTSKCTSB | |
| SCHEMBL1764798 | 0.88 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6162474 | 0.88 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788031-B1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED S L (ES) | 2023-09-27 | — | — | EP | disclosed |
| CN-112368263-B | Dipeptidyl ketoamide m-methoxyphenyl derivative and application thereof | 兰德施泰纳根梅德公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | LANDSTEINER GENMED, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2021-10-14 | — | — | US | disclosed |
| CN-112368263-A | Dipeptidyl ketoamide m-methoxyphenyl derivative and application thereof | 兰德施泰纳根梅德公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3564211-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| US-10159745-B2 | Tubulysin derivatives | MEDIMMUNE, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6270957-B1 | USEFUL IN THE TREATMENT AND PREVENTION OF HIV (HUMAN IMMUNODEFICIENCY VIRUS)-MEDIATED DISORDERS, INCLUDING AIDS (ACQUIRE IMMUNODEFICIENCY SYNDROME) | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-08-07 | — | — | US | disclosed |
| EP-0826671-A1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | THE GREEN CROSS CORPORATION (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | JAK3 4729/4885BTK 4610/4885CTSS 47/4885 |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | JAK3 4806/4885BTK 4489/4885CTSS 177/4885 |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | DPP4, DPP7, DPP3 | JAK3 3531/4885BTK 3583/4885CTSS 377/4885 |
| US-10159745-B2 | Tubulysin derivatives | TEKT1, TWF2, TEK | JAK3 3828/4885BTK 2857/4885CTSS 1158/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | JAK3 3828/4885BTK 2857/4885CTSS 1158/4885 |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | JAK3 3828/4885BTK 2857/4885CTSS 1158/4885 |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | DPP4, DPP7, DPP3 | JAK3 3531/4885BTK 3583/4885CTSS 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.